Cosentyx is indicated alone or in combination with methotrexate, for the treatment of active PsA in adult patients when the response to previous DMARDs has been inadequate; for the treatment of active AS in adults who have responded inadequately to conventional therapy and for the treatment of active nr-axSpA, with objective signs of inflammation, as indicated by elevated C-reactive protein and/or MRI evidence, in adults who have responded inadequately to NSAIDs.
Did you know?
Patients with axSpA often experience disrupted daily living, sleep, work, mobility and relationships**4–6
Cosentyx offers FAST and LASTING relief from the day-time and night-time symptoms of axSpA§‡1–3
NOW APPROVED for nr-axSpA4
64% of patients with nr-axSpA achieved ASDAS-CRP low/inactive disease after 1 year of treatment7
48% of patients with AS achieved ASDAS-CRP low/inactive disease after 5 years8
Dive into the data below to see how Cosentyx could help your patients with axSpA
Take the next step
We’re here to support you with dedicated representatives up and down the country. Let us connect you with your local representative to discuss how you can get the most out of Cosentyx.
Or find out more using the links below...
*150 mg s.c. load.
‡The primary endpoint of the MEASURE 2 study was ASAS20 response at Week 16 and was met (Cosentyx 150 mg: 61%, placebo: 28%; P<0.001)9
§The primary endpoint of the PREVENT study was ASAS40 response in biologic-naïve patients at Week 16 and was met (Cosentyx 150 mg: 42%, placebo: 29%; P<0.05)2
aPREVENT baseline values as observed in the overall population at Week 16 (Cosentyx 150 mg s.c. load vs placebo): Morning stiffness, 7.217 vs 6.597; spinal pain, 73.5 vs 71.1; fatigue, 21.828 vs 24.084; nocturnal pain, 70.8 vs 70.8.10–13
bMEASURE 2 baseline values as observed in the overall population at Week 16 (Cosentyx 150 mg s.c. load vs placebo): Morning stiffness, 6.848 vs 6.620; spinal pain, 66.953 vs 67.595; fatigue, 22.326 vs 23.256; nocturnal pain, 66.841 vs 63.867. Mean percentage change calculated as percentage of mean change from baseline.14–17
**Symptoms of axSpA include morning stiffness, spinal pain, fatigue, and nocturnal back pain.18
AS, ankylosing spondylitis; ASAS, Assessment in SpondyloArthritis international Society; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score C-reactive protein; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DMARD, disease-modifying antirheumatic drug; IL, interleukin; MRI, magnetic resonance imaging nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non -steroidal anti-inflammatory drug; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; s.c., subcutaneous; VAS, visual analogue scale.
- Cosentyx Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3669/smpc (Accessed January 2021).
- Deodhar A et al. Arthritis Rheumatol. 2020. doi: 10.1002/art.41477.
- Marzo-Ortega H et al. Lancet Rheumatol. 2020;2:e339–46.
- Heiberg T et al. Ann Rheum Dis. 2011;70:872–3.
- Ward MM et al. Arthritis Care Res. 1999;12:247–55.
- Garrido-Cumbrera M et al. Ann Rheum Dis. 2020;79:(suppl. 1). Abstract 4293.
- Rheumatology DOF UK 310.
- Rheumatology DOF UK 276.
- Baeten D et al. N Engl J Med. 2015:373:2534–48.
- Rheumatology DOF UK 304.
- Rheumatology DOF UK 305.
- Rheumatology DOF UK 306.
- Rheumatology DOF UK 307.
- Rheumatology DOF UK 270.
- Rheumatology DOF UK 271.
- Rheumatology DOF UK 272.
- Rheumatology DOF UK 273.
- Rudwaleit M et al. Arthritis Rheumatol. 2009;60:717–27.